Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of CRD-740 in Chronic Heart Failure (CARDINAL-HF)
NCT05409183Phase 2Terminated
- Sponsor
- Cardurion Pharmaceuticals
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of edelinontrine in heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), sponsored by Cardurion Pharmaceuticals. Started May 2022; status: terminated.
02
Drugs
edelinontrine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05409183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05409183.